A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Lauren A. Byers(The University of Texas MD Anderson Cancer Center), Martin Förster, Ji‐Youn Han(National Cancer Centre Japan), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Adam Abel(Eli Lilly (United States)), Alejandro Navarro(Vall d'Hebron Hospital Universitari), Melissa L. Johnson(Tennessee Oncology), Konstantin H. Dragnev(Dartmouth Cancer Center), Samuel McNeely(Eli Lilly (United States)), İrfan Çiçin(Istinye University), Xuejing Wang(University of Bern), Eric Schaefer(Highlands Oncology Group), Scott M. Hynes(Eli Lilly (United States)), Aimee Bence Lin(Eli Lilly (United States)), Igor Bondarenko(Dnipro State Medical University)
Clinical Lung Cancer
April 24, 2021
10.1016/j.cllc.2021.04.005
Cited by 39

Related Papers

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k